Arbutus Biopharma (ABUS) investor relations material

Executive summary

• Annual General and Special Meeting scheduled for May 26, 2026, with voting available online or in person.

• Shareholders are encouraged to review proxy materials and vote on key proposals affecting governance and compensation.

Voting matters and shareholder proposals

• Election of five director nominees to serve until the 2027 meeting or until successors are appointed.

• Approval of the 2026 Omnibus Share and Incentive Plan.

• Advisory vote on executive compensation (say-on-pay).

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Other business may be addressed as appropriate during the meeting.

Board of directors and corporate governance

• Five director nominees listed: Lindsay Androski, Robert Alan Beardsley, Joseph Bishop, Matthew Gline, Roger Sawhney.

• Directors to serve one-year terms, subject to re-election at the next annual meeting.